Announcement
01.02.2013
The NeuroSearch A/S (NEUR) financial statements 2012 will be released on Friday 8 February 2013.
On the same day, NeuroSearch will host a telephone conference at 9.30 am Copenhagen time (8.30 am London time, 3.30 am New York time) during which CEO René Schneider will present the financial statements 2012.
The telephone conference will be conducted in English and the dial-in numbers are:
| · UK: | +44 (0) 844 571 8957 |
| · US: | +1 866 682 8490 |
| · Denmark: | +45 32 72 80 18 |
Listening to the telephone conference is also possible via the company's website, www.neurosearch.com, where also the corresponding presentation will be available at the time of the telephone conference.
René Schneider
CEO
Contact person
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I.
All drug candidates exert their effect in the central nervous system.
